Developing specialized cancer, CNS and infectious disease pharmaceutical products

Nanopharmaceutics has built a deep pipeline of small molecule drug candidates to treat human cancer, CNS, and infectious diseases. Nanopharmaceutics' pipeline includes ten clinical-stage proprietary and partnered programs including Triapine®, Cloretazine™, and Z-Endoxifen in its cancer portfolio, NanoBUP , PRX-3140, NP-18-2, and NP-18-3 in its CNS portfolio, and Ramoplanin and NanoDOX in its infectious disease portfolio. Nanopharmaceutics is also advancing a large portfolio of R&D and preclinical development candidates.